Skip to main content

Day: December 9, 2024

Vow ASA: Preliminary results of the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Oslo, 9 December 2024: Reference is made to the stock exchange announcement published by Vow ASA (the “Company“) on 19 November 2024 regarding the approval by the extraordinary general meeting of the Company of a fully underwritten rights issue of 166,666,666 new shares in the Company (the “Offer Shares“), at a subscription price of NOK 1.50 per share...

Continue reading

Peapack-Gladstone Bank Hires Paula Gambino as Senior Vice President

PGCPaula Gambino, Senior Vice PresidentBEDMINSTER, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) — Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) and Peapack-Gladstone Bank are proud to announce that Paula Gambino has joined the Bank as a Senior Vice President, Head of SBA. Based in the Bank’s Headquarters in Bedminster, New Jersey, Paula plays a key role in expanding the Bank’s SBA business, dedicated to delivering exceptional, personalized service to both new and existing business clients. The U.S. Small Business Administration (SBA) aims to bolster the nation’s economy by assisting individuals in starting, building, and growing their businesses. The Bank’s SBA Lending Division offers custom-tailored support to qualifying small business owners, addressing their financial needs and fostering their success...

Continue reading

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

 Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications Management hosted a conference call during the ASH meeting on Sunday, December 8 discussing highlights of the presented data and next steps for the companyWATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, CA. This year’s presentations included updates from the BEACON and AURORA trials of bitopertin in patients with erythropoietic protoporphyria...

Continue reading

Ming Shing Group Holdings Limited Announces Closing of the Underwriter’s Over-Allotment Option in Connection with its Initial Public Offering

Hong Kong, Dec. 09, 2024 (GLOBE NEWSWIRE) — Ming Shing Group Holdings Limited (the “Company” or “Ming Shing”), (NASDAQ: MSW), a Hong Kong based company mainly engaged in wet trades works whose mission it is to become the leading wet trades works service provider in Hong Kong, today announced that it closed the sale of an additional 225,000 ordinary shares of the Company, pursuant to the full exercise of the underwriter’s over-allotment option granted in connection with the Company’s initial public offering (“IPO”, together with such over-allotment closing, the “Offering”), at the IPO price of $5.50 per share, less underwriting discounts. As a result, the Company has raised aggregate gross proceeds of $9,487,500, including the previously announced IPO gross proceeds of $8,250,000, prior to deducting underwriting discounts and commissions...

Continue reading

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; December 9, 2024Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in high-risk patients with previously untreated diffuse large B-cell lymphoma (DLBCL) Extended follow-up data from EPCORE® NHL-1 trial demonstrates durability of responses and long-term safety of epcoritamab monotherapy for patients with challenging-to-treat relapsed/refractory (R/R) DLBCL Both analyses were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH)Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult...

Continue reading

Eimskip’s Financial Calendar 2025

Birting stjórnendauppgjörs fyrir árið 2024      4. febrúar 2025Fjórði ársfjórðungur 2024, ársuppgjör og sjálfbærniupplýsingar 4. mars 2025Aðalfundur 2025 27. mars 2025Fyrsti ársfjórðungur 2025 13. maí 2025Annar ársfjórðungur 2025 26. ágúst 2025Þriðji ársfjórðungur 2025 4. nóvember 2025Birting stjórnendauppgjörs fyrir árið 2025            3. febrúar 2026Fjórði ársfjórðungur 2025, ársuppgjör og sjálfbærniupplýsingar 3. mars 2026Aðalfundur 2026 26. mars 2026Financial results will be disclosed and published after market closing. Please note that dates are subject to change. For further information please contact Guðbjörg Birna Björnsdóttir, Head of Treasury and Investor Relations via  investors@eimskip.com

Continue reading

Update on acquisition of treasury shares

Regulated information Aalst, Belgium, December 9, 2024 – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code of Companies and Associations, Ontex hereby discloses information in relation to its program to buy back treasury shares, which was announced on November 25, 2024.  During the week ending on December 6, 2024, Ontex repurchased 47,500 shares, as set out in the table below. As a result of these transactions, Ontex now holds 1,161,206 treasury shares, representing 1.41% of the total number of issued shares.             Date # shares Average price Min price Max price Total value02/12/2024 10,000 7.975 7.950 8.000 79,746.903/12/2024 10,000 7.965 7.950 7.980 79,650.004/12/2024 7,000 7.917 7.900 7.930 59,375.005/12/2024 10,000 7.933 7.910 7.950 79,325.006/12/2024 10,000 8.007 7.960 8.040 80,064.7On...

Continue reading

KLÉPIERRE: FOOTFALL JUMPS 7% AT KLÉPIERRE’S EUROPEAN MALLS OVER BLACK FRIDAY, WITH A SPIKE OF 13.3% IN FRANCE

PRESS RELEASE FOOTFALL JUMPS 7% AT KLÉPIERRE’S EUROPEAN MALLS OVER BLACK FRIDAY, WITH A SPIKE OF 13.3% IN FRANCE Paris, December 9, 2024 For Klépierre, the European leader in shopping malls, the festive shopping season has gotten off to a flying start: Klépierre saw footfall soar on Black Friday and throughout the subsequent weekend. Shoppers kicked off the festive shopping season in style across Europe. Footfall at Klépierre’s European centers jumped by 7% between November 29 and December 1, 2024, versus Black Friday 2023 and the subsequent weekend (November 24 to 26, 2023), translating into some 500,000 additional visitors over the three days. This trend was especially impressive in France, where footfall soared by 13.3%1. Our shopping centers in Iberia, Italy and the Netherlands also contributed significantly to the overall...

Continue reading

Lumibird : nombre de droits de vote et d’actions au 30 novembre 2024

Informations relatives au nombre total de droits de vote et d’actions prévues par les articles L.233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des Marchés FinanciersDate Nombre d’actions composantle capital Nombre réel de droits devote1 Nombre théorique droits devote230 novembre 202422 466 88233 683 59234 140 746(1)   Déduction faite des actions auto-détenues(2)   Y compris actions auto-détenues, en application de l’article 223-11, alinéa 2, du Règlementgénéral de l’Autorité des Marchés FinanciersAttachmentDROITS DE VOTE AU 30.11.2024

Continue reading

Roadzen Chosen by One of the World’s Largest LPG Carriers to Bring AI to its Fleet for Road Safety and Compliance

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN) (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced that a leading liquefied petroleum gas (LPG) supplier in India—a wholly owned subsidiary of one of the world’s largest LPG companies—will outfit its entire truck fleet with Roadzen’s drivebuddyAI. The system will monitor driver fatigue and provide real-time feedback to drive improvements in safety and compliance. Roadzen’s drivebuddyAI was selected following a comprehensive five-month validation process, competing against the world’s leading video telematics and ADAS vendors. The contract, which carries a term of five years for more than 500 vehicles, is expected to deliver over seven figures in revenue over the term. As the first...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.